{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:03:45Z","timestamp":1793865825560,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vascn.2026.108578","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:13Z","timestamp":1790955013000},"page":"108578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A contract research organization perspective on secondary pharmacology: current practices, panel selection, and emerging needs for interpretation"],"prefix":"10.1016","volume":"142","author":[{"given":"Emilie","family":"Desfosses","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie A.D.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Jolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vascn.2026.108578_bb0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/toxsci\/kfaf109","article-title":"De-risking seizure liability: Integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps","volume":"207","author":"Behl","year":"2025","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2026.108578_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106609","article-title":"Safety screening in early drug discovery: An optimized assay panel","volume":"99","author":"Bendels","year":"2019","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"12","key":"10.1016\/j.vascn.2026.108578_bb0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: The use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2026.108578_bb0020","article-title":"The state of the art in secondary pharmacology and its impact on the safety of new medicines","author":"Brennan","year":"2024","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.vascn.2026.108578_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117131","article-title":"In vitro pharmacologic profiling aids systemic toxicity assessment of chemicals","volume":"492","author":"Burbank","year":"2024","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2026.108578_bb0030","series-title":"Pistoia Alliance Spring Conference 2024","article-title":"In vitro pharmacology working group: the in vitro pharmacology working group","author":"Callahan","year":"2024"},{"issue":"2","key":"10.1016\/j.vascn.2026.108578_bb0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/toxsci\/kfy265","article-title":"Rationalizing secondary pharmacology screening using human genetic and pharmacological evidence","volume":"167","author":"Deaton","year":"2019","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2026.108578_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107098","article-title":"Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration","volume":"111","author":"Dodson","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108578_bb0045","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"10.1016\/j.vascn.2026.108578_bb0050","series-title":"S7B the Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (no. S7b)","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2005"},{"key":"10.1016\/j.vascn.2026.108578_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106869","article-title":"A practical guide to secondary pharmacology in drug discovery","volume":"105","author":"Jenkinson","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108578_bb0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vascn.2017.02.020","article-title":"Potential functional and pathological side effects related to off-target pharmacological activity","volume":"87","author":"Lynch","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2026.108578_bb0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nrd3845-c1","article-title":"Secondary pharmacology data to assess potential off-target activity of new drugs: A regulatory perspective","volume":"14","author":"Papoian","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"issue":"3","key":"10.1016\/j.vascn.2026.108578_bb0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0192623317690609","article-title":"Regulatory forum review*: Utility of in vitro secondary pharmacology data to assess risk of drug-induced Valvular heart disease in humans: Regulatory considerations","volume":"45","author":"Papoian","year":"2017","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2026.108578_bb0075","article-title":"Secondary pharmacology across therapeutic modalities: A cross-modality principle-based framework for off-target assessment","author":"Rosenbrier Ribeiro","year":"2026","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2026.108578_bb0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41573-025-01184-7","article-title":"Shaping secondary pharmacology panels of the future: Evolving target selection criteria for safety panels","volume":"24","author":"Schmidt","year":"2025","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.vascn.2026.108578_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107205","article-title":"Analysis of secondary pharmacology assays received by the US Food and Drug Administration","volume":"117","author":"Scott","year":"2022","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2026.108578_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40064-9","article-title":"A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs","volume":"14","author":"Sutherland","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.vascn.2026.108578_bb0095","series-title":"Assessment of abuse potential of drugs: Guidance for industry","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.vascn.2026.108578_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2026.106096","article-title":"Revisiting ICH S7A after 25 years: Outcomes of a multi-stakeholder workshop and strategic pillars for modernizing safety pharmacology","volume":"169","author":"Valentin","year":"2026","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.vascn.2026.108578_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2025.107763","article-title":"Results from an EFPIA, JPMA, PhRMA industry survey on reopening and revamping the ICH S7A guidance on safety and secondary pharmacology","volume":"135","author":"Valentin","year":"2025","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108578_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105368","article-title":"2000\u20132023 over two decades of ICH S7A: Has the time come for a revamp?","volume":"139","author":"Valentin","year":"2023","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.vascn.2026.108578_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105795","article-title":"Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology","volume":"159","author":"Valentin","year":"2025","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2026.108578_bb0120","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiological Reviews"},{"issue":"21","key":"10.1016\/j.vascn.2026.108578_bb0125","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S1359-6446(05)03632-9","article-title":"Keynote review: In vitro safety pharmacology profiling: An essential tool for successful drug development","volume":"10","author":"Whitebread","year":"2005","journal-title":"Drug Discovery Today"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:57:04Z","timestamp":1791575824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871926001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":25,"alternative-id":["S1056871926001711"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108578","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A contract research organization perspective on secondary pharmacology: current practices, panel selection, and emerging needs for interpretation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108578"}}